Greece lifts ban on drug exports; NICE ready to back 7 biologic RA meds;

@FiercePharma: ICYMI yesterday: Ireland plant with 100 workers on Sun's list for sale or closure. Item | Follow @FiercePharma

@EricPFierce: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Icahn casts his eye on Vivus with tender offer for convertible notes. More | Follow @CarlyHFierce

> Greece lifted its ban on re-export of a range of medications, instituted in July on worries of drug shortages during the country's financial crisis. Report

> U.K. cost-effectiveness watchdogs are preparing to recommend seven biologic treatments for rheumatoid arthritis, including two biosimilar meds. Report

> The market for snake antivenom in the U.S.--where prices can be more than $14,000 per vial, compared with a few hundred in other countries--illustrates the "broken" nature of the American system of paying for drugs, a researcher said. Report

> Pharmacy beneifts manager Express Scripts said its CEO, George Paz, would retire in May, to be replaced by its current president, Tim Wentworth. Report

> India may join a Geneva-based inspection cooperative to allow drug exporters to avoid multiple regulatory visits, but the effort could require some drugmakers to upgrade their manufacturing facilities. Report

Medical Device News

@FierceMedDev: Biogen CEO says the biotech aims to develop wearable and ingestible devices. More | Follow @FierceMedDev

@VarunSaxena2: Robotic surgery aspirant receives $4M+ in equity financing. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article | Follow @EmilyWFierce

> JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. More

> Delphinus raises $39M+ to back pivotal trial of more effective dense breast tissue ultrasound imaging. Article

Biotech News

@FierceBiotech: Penn scientists identify viral products that defend against respiratory syncytial virus. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Who you going to buy? Gilead banks $10B, stirring fresh buzz about a blockbuster buyout. Article | Follow @JohnCFierce

@DamianFierce: Flemming Ornskov, "avid postcard and letter writer" who keeps up on household chores. More | Follow @DamianFierce

> Clovis leaps as AstraZeneca's AZD9291 disappoints on lung cancer. Story

> CureVac turns to Cambridge, MA, to jump-start its mRNA pipeline. Item

> IBM debuts its hotly hyped 'cognitive cloud' health HQ in Cambridge. Article

> Takeda bets $500M on a freshly unstealthed biotech. Report

Vaccines News

> UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target. Item

> With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs. Report

> VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine. Story

> Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs. Article

> Merck's Zostavax not cost-effective for those in their 50s: Study. More

CRO News

> Aragen licenses a protein technology to speed up biologics R&D. Item

> Rho snags a $120M federal contract with NIH. Story

> Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis. Article

> Icon teams up with IBM to accelerate clinical trial startup. News

> Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15. Article

Pharma Manufacturing News

> Bangladesh-based Square Pharmaceuticals has two new plants online. Item

> Canada allows Apotex Indian plants to regain access to its markets. More

> GSK recalls more than 425K tubes of antibiotic cream. Report

> Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article

> Glaxo starts $153M plant in India. Story

Pharma Asia News

> Japan's Takeda gets U.S. FDA priority review for ixazomib. Item

> FT counts 39 plants banned in India as regulatory woes mount for drugmakers. More

> China Daily carries lengthy industry-linked op-ed against overuse of stents. Report

> Apotex sees Health Canada lift ban on two India plants. Story

> Chugai and Roche get U.S. FDA priority review on alectinib. Article

And Finally... A consumer test for cancer DNA hit the market amid worries about its interpretation. Report

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."